Vaidya Sane Ayurved Laboratories Limited (NSE:MADHAVBAUG)

Market Cap	1.92B +74.6%
Revenue (ttm)	1.07B +19.0%
Net Income	89.87M +25.9%
EPS	8.04 +38.4%
Shares Out	10.52M
PE Ratio	22.72
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	16,000
Open	180.20
Previous Close	182.70
Day's Range	180.20 - 184.00
52-Week Range	140.00 - 335.00
Beta	0.45
Analysts	n/a
Price Target	n/a
Earnings Date	May 15, 2026

About NSE:MADHAVBAUG

Vaidya Sane Ayurved Laboratories Limited, together with its subsidiaries, engages in the research, development, and sale of ayurvedic medicines and products in India. It operates through Sale of Product and Hospital Activity segments. The company sells medicines for arthritis and joint pains, cholesterol, diabetes, digestive, acidity, gastric, dyslipidemia, fever, cough, cold, general tonic, heart disease, hypertension/high blood pressure, liver, low glycemic index atta, obesity/weight management, piles and renal, skin, and wounds; and diet box...

• Industry: Medical Care Facilities
• Sector: Healthcare
• Founded: 1999
• Employees: 636
• Stock Exchange: National Stock Exchange of India
• Ticker Symbol: MADHAVBAUG

Financial Performance

In fiscal year 2026, NSE:MADHAVBAUG's revenue was 1.07 billion, an increase of 18.99% compared to the previous year's 898.47 million. Earnings were 89.87 million, an increase of 25.93%.